2021

  1. ICD-10-CM Codes
    2. ›
  2. C00-D49 Neoplasms
    3. ›
  3. C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissue
    4. ›
  4. C92- Myeloid leukemia
    5. ›
  5. 2021 ICD-10-CM Diagnosis Code C92

2021 ICD-10-CM Diagnosis Code C92

Myeloid leukemia

    2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
  • C92 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2021 edition of ICD-10-CM C92 became effective on October 1, 2020.
  • This is the American ICD-10-CM version of C92 - other international versions of ICD-10 C92 may differ.
Type 1 Excludes
Type 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as C92. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • personal history of leukemia (
    ICD-10-CM Diagnosis Code Z85.6

    Personal history of leukemia

      2016 2017 2018 2019 2020 2021 Billable/Specific Code POA Exempt
    Applicable To
    • Conditions classifiable to C91-C95
    Type 1 Excludes
    Z85.6
    )
Includes
Includes Help
"Includes" further defines, or give examples of, the content of the code or category.
  • granulocytic leukemia
  • myelogenous leukemia
The following code(s) above C92 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C92:
  • C00-D49
    2021 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C81-C96
    2021 ICD-10-CM Range C81-C96

    Malignant neoplasms of lymphoid, hematopoietic and related tissue

    Type 2 Excludes
    • Kaposi's sarcoma of lymph nodes (C46.3)
    • secondary and unspecified neoplasm of lymph nodes (C77.-)
    • secondary neoplasm of bone marrow (C79.52)
    • secondary neoplasm of spleen (C78.89)
    Malignant neoplasms of lymphoid, hematopoietic and related tissue
Clinical Information
  • A clonal proliferation of myeloid cells and their precursors in the bone marrow, peripheral blood, and spleen. When the proliferating cells are immature myeloid cells and myeloblasts, it is called acute myeloid leukemia. When the proliferating myeloid cells are neutrophils, it is called chronic myelogenous leukemia.
  • A progressive, proliferative disease of blood cells, originating from immature granulocytes.
  • Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (myeloid progenitor cells) in the bone marrow and other sites.
  • Leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors in the bone marrow and other sites.
Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
Code annotations containing back-references to C92:
  • Type 1 Excludes: D72.825
    ICD-10-CM Diagnosis Code D72.825

    Bandemia

      2016 2017 2018 2019 2020 2021 Billable/Specific Code
    Applicable To
    • Bandemia without diagnosis of specific infection
    Type 1 Excludes
ICD-10-CM Codes Adjacent To C92
C91.A1 …… in remission
C91.A2 …… in relapse
C91.Z Other lymphoid leukemia
C91.Z0 …… not having achieved remission
C91.Z1 …… in remission
C91.Z2 …… in relapse
C91.9 Lymphoid leukemia, unspecified
C91.90 …… not having achieved remission
C91.91 …… in remission
C91.92 …… in relapse
C92 Myeloid leukemia
C92.0 Acute myeloblastic leukemia
C92.00 …… not having achieved remission
C92.01 …… in remission
C92.02 …… in relapse
C92.1 Chronic myeloid leukemia, BCR/ABL-positive
C92.10 …… not having achieved remission
C92.11 …… in remission
C92.12 …… in relapse
C92.2 Atypical chronic myeloid leukemia, BCR/ABL-negative
C92.20 …… not having achieved remission

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Advertise with Us | License ICD10 Data

Copyright © | ICD10data.com